Developing shorter and more effective oral treatments for lung infections caused by Mycobacterium abscessus
Official title: Shorter and more effective oral regimens for M. abscessus pulmonary disease
Funded at Hackensack University Medical Center · NIH-11133092 · Data updated 2026-11-12
This study is looking for new pill-based treatments for people with lung infections caused by a tough bacteria called Mycobacterium abscessus, aiming to make it easier and more comfortable for patients to get better without needing IVs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | January 21, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $895,538 |
| NIH project number | 1R01AI184502-01A1 |
| Project ID | NIH-11133092 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pulmonary disease caused by Mycobacterium abscessus, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with pulmonary infections caused by other types of bacteria or those who do not have Mycobacterium abscessus may not benefit from this research.
What this research studies
This research focuses on finding new oral treatment regimens for patients suffering from pulmonary disease caused by Mycobacterium abscessus, a type of bacteria that is becoming increasingly resistant to existing antibiotics. The approach involves testing combinations of FDA-approved drugs and new candidates to create effective treatment plans that can be taken by mouth, reducing the need for lengthy and uncomfortable intravenous therapies. The research aims to identify regimens that can quickly reduce the bacterial load in patients, especially those with weakened immune systems, by using a combination of bactericidal and bacteriostatic agents. The effectiveness of these regimens will be evaluated through laboratory models before moving to clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to more effective and shorter treatment options for patients with Mycobacterium abscessus pulmonary disease.
How similar studies have gone: Previous research has shown promise in developing effective treatments for similar bacterial infections, but this specific approach is novel and untested.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Dick, Thomas — Hackensack University Medical Center
- Study coordinator: Dick, Thomas
Related research
Other NIH-funded projects on the same topics.
-
Ethics-aware Multimodal AI for COPD prevention, diagnosis, and treatment
A broad AI model uses diverse health data to help predict and manage COPD in people, with an emphasis on ethics and fairness.
-
New regimens to treat MAC lung disease in people with lung problems or weak immune systems
A study from Johns Hopkins aims to test new drug combinations to treat MAC lung disease in people with damaged lungs or weakened immune systems.
-
Positive airway pressure therapy for older veterans with COPD and sleep apnea overlap
A plan to see if using a CPAP/BAP therapy improves sleep, thinking, and quality of life for older veterans who have both COPD and sleep apnea.
-
Understanding how microbes and our bodies shape HIV-related COPD in LMICs
This project looks at how interactions between the human body and microbes may influence COPD in people living with HIV in low- and middle-income countries.
-
Anti-EMAP II antibody as a first-in-class treatment for COPD-related pulmonary hypertension
A first-in-class antibody treatment is being developed to help people with COPD-related pulmonary hypertension by blocking EMAP II, a molecule involved in lung injury and inflammation.
-
Non-coding RNA and COPD: how RNA structure changes with disease
A COPD research project explores how non-coding RNA structures in adults with COPD change due to genetic differences and how this affects gene activity.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.